Marlene Chernow

545 total citations
9 papers, 445 citations indexed

About

Marlene Chernow is a scholar working on Epidemiology, Virology and Infectious Diseases. According to data from OpenAlex, Marlene Chernow has authored 9 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Virology and 3 papers in Infectious Diseases. Recurrent topics in Marlene Chernow's work include HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). Marlene Chernow is often cited by papers focused on HIV Research and Treatment (4 papers), HIV/AIDS drug development and treatment (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). Marlene Chernow collaborates with scholars based in United States, Poland and Switzerland. Marlene Chernow's co-authors include Thomas R. Matthews, Richard Boehme, Donald F. Smee, Jonathan A. Leff, Dave Singh, Geoffrey Yarranton, Chad K. Oh, Brian J. Sutton, Néstor A. Molfino and Piotr Kuna and has published in prestigious journals such as The Lancet, Antimicrobial Agents and Chemotherapy and Biochemical Pharmacology.

In The Last Decade

Marlene Chernow

9 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marlene Chernow United States	8	252	128	104	102	71	9	445
Stephen K. Tyring United States	10	304 1.2×	57 0.4×	58 0.6×	93 0.9×	37 0.5×	14	464
Enok Tjøtta Norway	8	255 1.0×	102 0.8×	36 0.3×	146 1.4×	65 0.9×	15	397
Eugene DeStefano United States	8	278 1.1×	118 0.9×	250 2.4×	56 0.5×	29 0.4×	8	484
Nicola Mongiardo Italy	10	192 0.8×	230 1.8×	171 1.6×	178 1.7×	84 1.2×	19	500
Gustav Gilljam Sweden	13	212 0.8×	326 2.5×	136 1.3×	296 2.9×	129 1.8×	21	592
Bertrand Georges France	12	240 1.0×	41 0.3×	259 2.5×	110 1.1×	172 2.4×	26	529
M. Fóns United States	15	392 1.6×	43 0.3×	211 2.0×	64 0.6×	154 2.2×	27	649
J.-P. Vendrell France	11	76 0.3×	99 0.8×	189 1.8×	31 0.3×	35 0.5×	16	320
S.F. Josephs United States	9	402 1.6×	111 0.9×	64 0.6×	175 1.7×	130 1.8×	14	615
Jacob T. Minang Sweden	14	69 0.3×	108 0.8×	209 2.0×	43 0.4×	65 0.9×	23	486

Countries citing papers authored by Marlene Chernow

Since Specialization

Citations

This map shows the geographic impact of Marlene Chernow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marlene Chernow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marlene Chernow more than expected).

Fields of papers citing papers by Marlene Chernow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marlene Chernow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marlene Chernow. The network helps show where Marlene Chernow may publish in the future.

Co-authorship network of co-authors of Marlene Chernow

This figure shows the co-authorship network connecting the top 25 collaborators of Marlene Chernow. A scholar is included among the top collaborators of Marlene Chernow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marlene Chernow. Marlene Chernow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Molfino, Néstor A., Piotr Kuna, Jonathan A. Leff, et al.. (2016). Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open. 6(1). e007709–e007709. 46 indexed citations

Pitisuttithum, Punnee, Phillip W. Berman, Benjaluck Phonrat, et al.. (2004). Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(1). 1160–1165. 50 indexed citations

Eron, Joseph J., Mark Ashby, Marlene Chernow, et al.. (1996). Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. The Lancet. 348(9041). 1547–1551. 54 indexed citations

Wu, Joseph C., Marlene Chernow, Richard Boehme, et al.. (1988). Kinetics and inhibition of reverse transcriptase from human and simian immunodeficiency viruses. Antimicrobial Agents and Chemotherapy. 32(12). 1887–1890. 16 indexed citations

Smee, Donald F., Marlene Chernow, Monica Kraft, Patricia M. Okamoto, & Ernest J. Prisbe. (1988). Synthesis and Anti-Herpetic Activity of A 2′-Fluoroarabinosyl Analog of Trifluridine. Nucleosides and Nucleotides. 7(2). 155–165. 4 indexed citations

Smee, Donald F., et al.. (1986). In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses. Antiviral Research. 6(5). 299–308. 27 indexed citations

Smee, Donald F., et al.. (1985). Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl) guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochemical Pharmacology. 34(7). 1049–1056. 119 indexed citations

Smee, Donald F., et al.. (1985). Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrobial Agents and Chemotherapy. 28(2). 240–245. 106 indexed citations

Péter, G, et al.. (1982). Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia. Infection. 10(4). 228–232. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact